| 000 | 01830 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515035250.0 | ||
| 264 | 0 | _c20061003 | |
| 008 | 200610s 0 0 eng d | ||
| 022 | _a0949-2321 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVogel, M | |
| 245 | 0 | 0 |
_aStructured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. _h[electronic resource] |
| 260 |
_bEuropean journal of medical research _cJul 2006 |
||
| 300 |
_a273-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xmethods |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _ximmunology |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _ximmunology |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHIV Seropositivity _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xgenetics |
| 650 | 0 | 4 | _aHistocompatibility Testing |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLamivudine _xtherapeutic use |
| 650 | 0 | 4 | _aLopinavir |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPyrimidinones _xtherapeutic use |
| 650 | 0 | 4 |
_aRNA, Viral _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aStavudine _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aZidovudine _xtherapeutic use |
| 700 | 1 | _aLichterfeld, M | |
| 700 | 1 | _aKaufmann, D E | |
| 700 | 1 | _aMui, S K | |
| 700 | 1 | _aAltfeld, M | |
| 700 | 1 | _aVoigt, E | |
| 700 | 1 | _aAhlenstiel, G | |
| 700 | 1 | _aKupfer, B | |
| 700 | 1 | _aWalker, B | |
| 700 | 1 | _aSpengler, U | |
| 700 | 1 | _aRockstroh, J K | |
| 773 | 0 |
_tEuropean journal of medical research _gvol. 11 _gno. 7 _gp. 273-8 |
|
| 999 |
_c16487235 _d16487235 |
||